Asia Pacific Autoinjectors Market By Type (Disposable autoinjectors and Reusable autoinjectors), By Application (Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications), By End Use (Hospitals & Clinics and Home care settings), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Autoinjectors Market
The Asia Pacific Autoinjectors Market would witness market growth of 19.1% CAGR during the forecast period (2020-2026). Most of the autoinjectors are single-use, disposable, spring-loaded syringes. The autoinjectors are designed in such a way that it makes them easy to use and are planned for self-administration by patients, or delivered by even untrained personnel.
The place of injection mainly depends on the drug-loaded, but it is usually administered into either thigh or buttocks. Auto-injectors are favored over conventional devices because they allow efficient and enhanced drug delivery even in new formulations. The advancement of technology in products are estimated to boost growth.
Market growth is mainly driven by the increasing incidences of targeted therapies, the increasing occurrence of anaphylaxis, growing inclination for self-administration of drugs. Further, the usability benefits, the growing number of governing approvals, and the accessibility of standard versions of autoinjectors, favorable settlements pertaining to the autoinjectors is fuelling the market. In addition, government’s provision as well as technological advancements are likely to turn this market more opportunistic. The patent termination of biologics is also anticipated to deliver growth opportunities for the market.
The growth of the market in the Asia Pacific market is largely due to the large number of patients suffering from chronic allergies and diabetes as well as increasing healthcare expenditure. This in turn has drawn a number of key auto-injector device manufacturers to this region. These companies are showing more presence in the Asia Pacific market via several approaches, including partnering with local pharmaceutical companies and establishing sales offices.
Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
Scope of the Study
Market Segments Covered in the Report:
- Disposable autoinjectors
- Reusable autoinjectors
- Rheumatoid Arthritis
- Multiple Sclerosis
- Other Applications
By End Use
- Hospitals & Clinics
- Home care settings
- South Korea
- Rest of Asia Pacific
- Eli Lilly and Company
- GlaxoSmithKline PLC (GSK)
- Merck Group
- Sanofi S.A.
- Becton, Dickinson and Company
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- Ypsomed AG
- AbbVie, Inc.
- Biogen, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free